Comparative analysis of the quality of platelet concentrates produced by apheresis procedures, platelet rich plasma, and buffy coat
- 4 January 2024
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 64 (2) , 367-379
Abstract
Background: Platelet concentrates (PCs) could be prepared using either whole‐blood processes or apheresis instruments. During collection, processing and storage, some biochemical and functional changes occur, which may result in quality reduction. Quality evaluation of PCs may be helpful for the precise control of platelet (PLT) inventory to reduce the risk of refractoriness and adverse effects caused by platelet transfusion.Study Design and Methods: The study was aimed to evaluate the quality of PCs which were produced by five processes: apheresis (AP) procedures (using three different cell separators: Amicus, Trima Accel and MCS+ instruments), platelet rich plasma (PRP), and buffy coat (BC). A total of 100 PCs (20 of each group) were assessed in respect of routine quality control, morphology, size distribution, destroyed and activated platelets, and production of platelet‐derived microparticles (PMPs).Results: All PCs have satisfied the recommended quality of volume, platelet count, residual WBC count, residual RBC count, pH, and sterility according to the Chinese Technical Manual. There was no difference among the 5 groups in morphology and size of PLT and PMPs. Dynamic light scattering test showed that apheresis PCs showed peaks around 10–20 nm, but not whole blood‐derived PCs. PCs prepared by Amicus had the relatively high percentage of destroyed platelet, activated platelets and PMPs than other groups.Discussion: The data suggested high heterogeneity of PMPs, destroyed and activated platelets in PCs produced by different processes, which might be helpful to manage the platelet inventory for targeted use.Keywords
This publication has 54 references indexed in Scilit:
- Microparticles in Health and DiseaseJournal of Veterinary Internal Medicine, 2013
- Microparticles in Hemostasis and ThrombosisCirculation Research, 2011
- Time to rethink clinically important outcomes in platelet transfusion trialsTransfusion, 2010
- Stored platelet concentrates produced by the platelet‐rich plasma method are more resistant to apoptosis but more sensitive to activation than are platelets prepared by the buffy‐coat and apheresis methodsTransfusion, 2009
- Quality assessment of platelet concentrates prepared by platelet rich plasma-platelet concentrate, buffy coat poor-platelet concentrate (BC-PC) and apheresis-PC methodsAsian Journal of Transfusion Science, 2009
- Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic reviewTransfusion, 2008
- Therapeutic efficacy of different types of platelet concentrates in thrombocytopenic patientsIndian Journal of Hematology and Blood Transfusion, 2008
- Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancerInternational Journal of Cancer, 2004
- Quantitation of CD62, soluble CD62, and lysosome‐associated membrane proteins 1 and 2 for evaluation of the quality of stored platelet concentratesTransfusion, 1995
- Paired in vivo and in vitro comparison of apheresis and “recovered” platelet concentrates stored for 5 daysJournal of Clinical Apheresis, 1994